Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 10/10

vs
industry
vs
history
Cash-to-Debt No Debt
IRMD's Cash-to-Debt is ranked higher than
83% of the 330 Companies
in the Global Medical Devices industry.

( Industry Median: 2.32 vs. IRMD: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
IRMD' s Cash-to-Debt Range Over the Past 10 Years
Min: 3.75  Med: No Debt Max: No Debt
Current: No Debt
3.75
No Debt
Equity-to-Asset 0.87
IRMD's Equity-to-Asset is ranked higher than
83% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. IRMD: 0.87 )
Ranked among companies with meaningful Equity-to-Asset only.
IRMD' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.58  Med: 0.86 Max: 0.91
Current: 0.87
0.58
0.91
Interest Coverage No Debt
IRMD's Interest Coverage is ranked higher than
81% of the 212 Companies
in the Global Medical Devices industry.

( Industry Median: 66.37 vs. IRMD: No Debt )
Ranked among companies with meaningful Interest Coverage only.
IRMD' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 8
Altman Z-Score: 30.84
Beneish M-Score: -2.45
WACC vs ROIC
14.84%
84.73%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 19.72
IRMD's Operating Margin % is ranked higher than
58% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 1.96 vs. IRMD: 19.72 )
Ranked among companies with meaningful Operating Margin % only.
IRMD' s Operating Margin % Range Over the Past 10 Years
Min: 5.57  Med: 19.72 Max: 36.44
Current: 19.72
5.57
36.44
Net Margin % 20.71
IRMD's Net Margin % is ranked higher than
52% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 1.40 vs. IRMD: 20.71 )
Ranked among companies with meaningful Net Margin % only.
IRMD' s Net Margin % Range Over the Past 10 Years
Min: 2.17  Med: 17.08 Max: 23.83
Current: 20.71
2.17
23.83
ROE % 17.00
IRMD's ROE % is ranked higher than
52% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 0.95 vs. IRMD: 17.00 )
Ranked among companies with meaningful ROE % only.
IRMD' s ROE % Range Over the Past 10 Years
Min: 1.54  Med: 22.61 Max: 44.82
Current: 17
1.54
44.82
ROA % 14.50
IRMD's ROA % is ranked higher than
55% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: -0.26 vs. IRMD: 14.50 )
Ranked among companies with meaningful ROA % only.
IRMD' s ROA % Range Over the Past 10 Years
Min: 1.31  Med: 17.39 Max: 30.89
Current: 14.5
1.31
30.89
ROC (Joel Greenblatt) % 85.61
IRMD's ROC (Joel Greenblatt) % is ranked higher than
69% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 3.87 vs. IRMD: 85.61 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
IRMD' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 20.51  Med: 104.3 Max: 277.09
Current: 85.61
20.51
277.09
3-Year EBITDA Growth Rate -15.70
IRMD's 3-Year EBITDA Growth Rate is ranked lower than
78% of the 232 Companies
in the Global Medical Devices industry.

( Industry Median: 7.50 vs. IRMD: -15.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
IRMD' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -15.7  Med: 20.55 Max: 88.3
Current: -15.7
-15.7
88.3
3-Year EPS without NRI Growth Rate -4.70
IRMD's 3-Year EPS without NRI Growth Rate is ranked lower than
89% of the 223 Companies
in the Global Medical Devices industry.

( Industry Median: 7.80 vs. IRMD: -4.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
IRMD' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -41.5  Med: 17.5 Max: 76
Current: -4.7
-41.5
76
GuruFocus has detected 2 Warning Signs with iRadimed Corp IRMD.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» IRMD's 30-Y Financials

Financials (Next Earnings Date: 2019-04-30)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2018

IRMD Guru Trades in Q1 2018

Jim Simons 53,458 sh (+11.91%)
» More
Q2 2018

IRMD Guru Trades in Q2 2018

Jim Simons 117,200 sh (+119.24%)
» More
Q3 2018

IRMD Guru Trades in Q3 2018

Chuck Royce 460 sh (New)
Caxton Associates 16,448 sh (New)
Jim Simons 198,700 sh (+69.54%)
» More
Q4 2018

IRMD Guru Trades in Q4 2018

Jim Simons 320,500 sh (+61.30%)
Chuck Royce 438 sh (-4.78%)
Caxton Associates 8,690 sh (-47.17%)
» More
» Details

Insider Trades

Latest Guru Trades with IRMD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 334510    SIC: 3841
Compare:ASX:OSP, XCNQ:BLO, ASX:SOM, XPAR:QUA, NAS:SPNE, HKSE:01858, ROCO:4126, XKRX:044480, XKRX:122450, ROCO:4129, XKRX:065510, NAS:FONR, WAR:MDG, OTCPK:ZYXI, TSE:3079, NAS:NVTR, ASX:RVA, ROCO:1752, NAS:VIVE, NAS:TNDM » details
Headquarter Location:USA
iRadimed Corp develops, manufactures, markets and distributes Magnetic Resonance Imaging compatible products to acute care facilities and outpatient imaging centers, both in the United States and internationally.

iRadimed Corp is a US-based company which mainly develops, manufactures, markets and distributes a magnetic resonance imaging (MRI) compatible intravenous (IV) infusion pump system, an MRI compatible patient vital signs monitoring system and accessories and services relating to them. The company provides non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold primarily to hospitals and acute care facilities in the United States and internationally.

Top Ranked Articles about iRadimed Corp

Outperformance and Thinking Differently, Part 2: Allocating Time How a value investor sees and values time can dramatically impact long-term performance
There is an old story about Hubert Lyautey, a French army marshal, elder statesman and former administrator of the French colony of Morocco. In the story, Lyautey goes to his gardener one day and asks him to plant a certain type of tree in the back garden of his chateau. The gardener objected, knowing the tree grew at a remarkably slow pace and that it wouldn’t flower for at least a century. “In that case,” Lyautey replied, “there is no time to lose. Plant it this afternoon.” Read more...
IRADIMED CORPORATION Expects Minor Impact to 2019 Revenue After Temporarily Suspending Shipments of MRI Compatible Patient Vital Signs Monitoring Systems in European Markets
IRADIMED CORPORATION to Hold 2018 Fourth Quarter Financial Results Conference Call on February 6th
IRADIMED CORPORATION Announces 510(k) Clearance of Invasive Blood Pressure Module for use with its MRI-Compatible Patient Vital Signs Monitor
IRADIMED CORPORATION to Hold 2018 Third Quarter Financial Results Conference Call on October 30th
IRADIMED CORPORATION to Hold 2018 Second Quarter Financial Results Conference Call on July 31st
IRADIMED CORPORATION to Hold 2018 First Quarter Financial Results Conference Call on April 30th

Ratios

vs
industry
vs
history
PE Ratio 54.10
IRMD's PE Ratio is ranked lower than
97% of the 180 Companies
in the Global Medical Devices industry.

( Industry Median: 30.17 vs. IRMD: 54.10 )
Ranked among companies with meaningful PE Ratio only.
IRMD' s PE Ratio Range Over the Past 10 Years
Min: 13.33  Med: 66.68 Max: 516.67
Current: 54.1
13.33
516.67
Forward PE Ratio 38.91
IRMD's Forward PE Ratio is ranked lower than
83% of the 52 Companies
in the Global Medical Devices industry.

( Industry Median: 25.06 vs. IRMD: 38.91 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 54.10
IRMD's PE Ratio without NRI is ranked lower than
97% of the 179 Companies
in the Global Medical Devices industry.

( Industry Median: 30.17 vs. IRMD: 54.10 )
Ranked among companies with meaningful PE Ratio without NRI only.
IRMD' s PE Ratio without NRI Range Over the Past 10 Years
Min: 13.33  Med: 66.68 Max: 516.67
Current: 54.1
13.33
516.67
Price-to-Owner-Earnings 71.58
IRMD's Price-to-Owner-Earnings is ranked lower than
99% of the 104 Companies
in the Global Medical Devices industry.

( Industry Median: 32.03 vs. IRMD: 71.58 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
IRMD' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 51.07  Med: 95.39 Max: 3126
Current: 71.58
51.07
3126
PB Ratio 7.33
IRMD's PB Ratio is ranked lower than
63% of the 310 Companies
in the Global Medical Devices industry.

( Industry Median: 3.06 vs. IRMD: 7.33 )
Ranked among companies with meaningful PB Ratio only.
IRMD' s PB Ratio Range Over the Past 10 Years
Min: 2.75  Med: 6.12 Max: 12.56
Current: 7.33
2.75
12.56
PS Ratio 11.16
IRMD's PS Ratio is ranked lower than
71% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 3.15 vs. IRMD: 11.16 )
Ranked among companies with meaningful PS Ratio only.
IRMD' s PS Ratio Range Over the Past 10 Years
Min: 3.05  Med: 7.23 Max: 15.43
Current: 11.16
3.05
15.43
Price-to-Free-Cash-Flow 47.92
IRMD's Price-to-Free-Cash-Flow is ranked lower than
80% of the 107 Companies
in the Global Medical Devices industry.

( Industry Median: 26.44 vs. IRMD: 47.92 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
IRMD' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 12.52  Med: 40.27 Max: 120.37
Current: 47.92
12.52
120.37
Price-to-Operating-Cash-Flow 46.20
IRMD's Price-to-Operating-Cash-Flow is ranked lower than
82% of the 127 Companies
in the Global Medical Devices industry.

( Industry Median: 20.01 vs. IRMD: 46.20 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
IRMD' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 10.51  Med: 36.19 Max: 100.54
Current: 46.2
10.51
100.54
EV-to-EBIT 45.80
IRMD's EV-to-EBIT is ranked lower than
92% of the 174 Companies
in the Global Medical Devices industry.

( Industry Median: 24.76 vs. IRMD: 45.80 )
Ranked among companies with meaningful EV-to-EBIT only.
IRMD' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.6  Med: 36.55 Max: 122.3
Current: 45.8
6.6
122.3
EV-to-EBITDA 38.69
IRMD's EV-to-EBITDA is ranked lower than
85% of the 188 Companies
in the Global Medical Devices industry.

( Industry Median: 18.14 vs. IRMD: 38.69 )
Ranked among companies with meaningful EV-to-EBITDA only.
IRMD' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6  Med: 32.85 Max: 66
Current: 38.69
6
66
EV-to-Revenue 9.03
IRMD's EV-to-Revenue is ranked lower than
62% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 3.73 vs. IRMD: 9.03 )
Ranked among companies with meaningful EV-to-Revenue only.
IRMD' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.2  Med: 6.4 Max: 14.6
Current: 9.03
2.2
14.6
PEG Ratio 6.81
IRMD's PEG Ratio is ranked lower than
92% of the 77 Companies
in the Global Medical Devices industry.

( Industry Median: 2.53 vs. IRMD: 6.81 )
Ranked among companies with meaningful PEG Ratio only.
IRMD' s PEG Ratio Range Over the Past 10 Years
Min: 6.23  Med: 7.89 Max: 9.41
Current: 6.81
6.23
9.41
Current Ratio 9.50
IRMD's Current Ratio is ranked higher than
92% of the 324 Companies
in the Global Medical Devices industry.

( Industry Median: 2.71 vs. IRMD: 9.50 )
Ranked among companies with meaningful Current Ratio only.
IRMD' s Current Ratio Range Over the Past 10 Years
Min: 2.14  Med: 9.25 Max: 11.73
Current: 9.5
2.14
11.73
Quick Ratio 8.63
IRMD's Quick Ratio is ranked higher than
92% of the 324 Companies
in the Global Medical Devices industry.

( Industry Median: 2.03 vs. IRMD: 8.63 )
Ranked among companies with meaningful Quick Ratio only.
IRMD' s Quick Ratio Range Over the Past 10 Years
Min: 1.55  Med: 8.18 Max: 10.9
Current: 8.63
1.55
10.9
Days Inventory 215.47
IRMD's Days Inventory is ranked lower than
80% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 143.61 vs. IRMD: 215.47 )
Ranked among companies with meaningful Days Inventory only.
IRMD' s Days Inventory Range Over the Past 10 Years
Min: 140.91  Med: 185.91 Max: 265.33
Current: 215.47
140.91
265.33
Days Sales Outstanding 50.48
IRMD's Days Sales Outstanding is ranked higher than
64% of the 276 Companies
in the Global Medical Devices industry.

( Industry Median: 69.21 vs. IRMD: 50.48 )
Ranked among companies with meaningful Days Sales Outstanding only.
IRMD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 42.41  Med: 50.48 Max: 75.28
Current: 50.48
42.41
75.28
Days Payable 39.07
IRMD's Days Payable is ranked lower than
64% of the 261 Companies
in the Global Medical Devices industry.

( Industry Median: 58.34 vs. IRMD: 39.07 )
Ranked among companies with meaningful Days Payable only.
IRMD' s Days Payable Range Over the Past 10 Years
Min: 39.07  Med: 62.81 Max: 70.05
Current: 39.07
39.07
70.05

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 0.80
IRMD's 3-Year Average Share Buyback Ratio is ranked higher than
91% of the 244 Companies
in the Global Medical Devices industry.

( Industry Median: -5.70 vs. IRMD: 0.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
IRMD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -2.4  Med: -0.15 Max: 0.8
Current: 0.8
-2.4
0.8

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 11.03
IRMD's Price-to-Net-Cash is ranked higher than
76% of the 104 Companies
in the Global Medical Devices industry.

( Industry Median: 14.24 vs. IRMD: 11.03 )
Ranked among companies with meaningful Price-to-Net-Cash only.
IRMD' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 5.84  Med: 9.35 Max: 13.22
Current: 11.03
5.84
13.22
Price-to-Net-Current-Asset-Value 8.08
IRMD's Price-to-Net-Current-Asset-Value is ranked higher than
65% of the 207 Companies
in the Global Medical Devices industry.

( Industry Median: 7.79 vs. IRMD: 8.08 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
IRMD' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 4.17  Med: 7.03 Max: 10.23
Current: 8.08
4.17
10.23
Price-to-Tangible-Book 7.48
IRMD's Price-to-Tangible-Book is ranked higher than
50% of the 276 Companies
in the Global Medical Devices industry.

( Industry Median: 4.50 vs. IRMD: 7.48 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
IRMD' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.84  Med: 6.5 Max: 9.87
Current: 7.48
3.84
9.87
Price-to-Intrinsic-Value-Projected-FCF 3.34
IRMD's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
99.99% of the 121 Companies
in the Global Medical Devices industry.

( Industry Median: 2.44 vs. IRMD: 3.34 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
IRMD' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 2.9  Med: 2.9 Max: 3.35
Current: 3.34
2.9
3.35
Price-to-Median-PS-Value 1.55
IRMD's Price-to-Median-PS-Value is ranked higher than
54% of the 237 Companies
in the Global Medical Devices industry.

( Industry Median: 1.02 vs. IRMD: 1.55 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
IRMD' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.57  Med: 1.25 Max: 1.55
Current: 1.55
0.57
1.55
Price-to-Peter-Lynch-Fair-Value 8.82
IRMD's Price-to-Peter-Lynch-Fair-Value is ranked lower than
99.99% of the 47 Companies
in the Global Medical Devices industry.

( Industry Median: 2.05 vs. IRMD: 8.82 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
IRMD' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 7.67  Med: 7.67 Max: 8.84
Current: 8.82
7.67
8.84
Price-to-Graham-Number 4.24
IRMD's Price-to-Graham-Number is ranked lower than
92% of the 133 Companies
in the Global Medical Devices industry.

( Industry Median: 2.11 vs. IRMD: 4.24 )
Ranked among companies with meaningful Price-to-Graham-Number only.
IRMD' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.78  Med: 4.4 Max: 9.18
Current: 4.24
1.78
9.18
Earnings Yield (Greenblatt) % 2.19
IRMD's Earnings Yield (Greenblatt) % is ranked higher than
52% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: 0.74 vs. IRMD: 2.19 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
IRMD' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.8  Med: 2.75 Max: 15.3
Current: 2.19
0.8
15.3
Forward Rate of Return (Yacktman) % 7.73
IRMD's Forward Rate of Return (Yacktman) % is ranked lower than
99.99% of the 125 Companies
in the Global Medical Devices industry.

( Industry Median: 6.60 vs. IRMD: 7.73 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
IRMD' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 7.7  Med: 8 Max: 11.7
Current: 7.73
7.7
11.7

More Statistics

Revenue (TTM) (Mil) $30.44
EPS (TTM) $ 0.52
Beta2.05
Volatility62.80%
52-Week Range $13.75 - 38.78
Shares Outstanding (Mil)11.00

Analyst Estimate

Dec19 Dec20 Dec21
Revenue (Mil $) 39 48 59
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) 0.62 0.89 1.24
EPS without NRI ($) 0.62 0.89 1.24
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 88
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}